Intersect ENT, Inc
XENT
XENT was delisted on the 12th of May, 2022.
121 hedge funds and large institutions have $331M invested in Intersect ENT, Inc in 2020 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 47 increasing their positions, 32 reducing their positions, and 19 closing their positions.
442% more call options, than puts
Call options by funds: $2.48M | Put options by funds: $457K
47% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 32
21% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 19
1% more funds holding
Funds holding: 120 → 121 (+1)
57% less capital invested
Capital invested by funds: $776M → $331M (-$445M)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$35.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$18.1M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$15.5M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
+$13.2M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$8.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$63.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$39M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$29M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$18.8M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$14.9M |
XENT Hedge Fund Activity: Q1 2020 in Review
121 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Intersect ENT, Inc (XENT) for Q1 2020, worth a combined $331M — down 57% from $776M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new XENT positions and 19 closed out — a net gain of 4 holders — while 47 added to existing stakes and 32 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $35.1M. The largest seller was HealthCor Management, exiting entirely with an estimated $63.2M sold.
- 121 institutional investors held Intersect ENT, Inc (XENT) as of Q1 2020, up from 120 in Q4 2019.
- Funds reported $331M of Intersect ENT, Inc stock for Q1 2020, down 57% quarter-over-quarter.
- 23 funds opened new Intersect ENT, Inc positions in Q1 2020 and 19 closed out, a net change of +4 holders.
- The largest Intersect ENT, Inc buyer in Q1 2020 was Fidelity Investments, an estimated $35.1M added.
- The largest Intersect ENT, Inc seller in Q1 2020 was HealthCor Management, an estimated $63.2M sold.
Based on aggregated 13F filings for Q1 2020.